NCT05775406
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
Registry record
- Lead sponsor
- Kymera Therapeutics, Inc.
- Conditions
- Myeloid Malignancies; Acute Lymphocytic Leukemia; Lymphomas; Advanced Solid Tumors
- Primary completion
- Dec 18, 2024Actual
- Completion
- Locked
- Start
- Locked
- Enrollment
- Locked
- Interventions
- Locked
- Study type
- Locked
- Results on the registry
- Locked
- Record last updated
- Locked
Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerRecorded changes
0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.
Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.